Expert Interview
A 3rd View: A discussion of Nexletol (Bempedoic acid) and CLEAR Cardiovascular Outcome Trial ahead of detailed data at ACC
Ticker(s): ESPRInstitution: UCLA
- Professor of Medicine and Endowed Chair of Preventive Cardiology at UCLA.
- Treats hundreds of patients with hypertriglyceridemia and has been in practice 25 years advancing procedures that can help doctors identify cardiac patients early and place them on a therapeutic path to prevent a heart attack.
- Works on at least 20 active medical research trials at any given time, and has authored or co-authored over 800 research papers, seven books, and 45 book chapters.
Do you think the lack of outcomes data has been a significant contributor to the lower revenue for Nexletol compared to Inclisiran?
The data from the Phase III studies shows a small decrease in weight and glycemic control. Do you consider this meaningful?
Added By: slingshot_insightsHow's your experience with Esperion sales reps been, either before or after the layoffs?
Do you have any thoughts on the Verve Therapeutics, they're using gene editing to lower LDL?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
